HK1202560A1 - Light chain-bridged bispecific antibody - Google Patents
Light chain-bridged bispecific antibodyInfo
- Publication number
- HK1202560A1 HK1202560A1 HK15102984.7A HK15102984A HK1202560A1 HK 1202560 A1 HK1202560 A1 HK 1202560A1 HK 15102984 A HK15102984 A HK 15102984A HK 1202560 A1 HK1202560 A1 HK 1202560A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- light chain
- bispecific antibody
- bridged
- bridged bispecific
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580491P | 2011-12-27 | 2011-12-27 | |
PCT/US2012/071780 WO2013101909A1 (fr) | 2011-12-27 | 2012-12-27 | Anticorps bispécifique à chaîne légère pontée |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202560A1 true HK1202560A1 (en) | 2015-10-02 |
Family
ID=48655211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102984.7A HK1202560A1 (en) | 2011-12-27 | 2015-03-24 | Light chain-bridged bispecific antibody |
Country Status (10)
Country | Link |
---|---|
US (1) | US20130165638A1 (fr) |
EP (1) | EP2797958B1 (fr) |
JP (2) | JP6114902B2 (fr) |
KR (2) | KR101814370B1 (fr) |
CN (1) | CN104185642A (fr) |
AU (1) | AU2012362378B2 (fr) |
CA (1) | CA2861816C (fr) |
HK (1) | HK1202560A1 (fr) |
TW (1) | TWI530505B (fr) |
WO (1) | WO2013101909A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104144949B (zh) * | 2011-12-22 | 2016-08-31 | 财团法人生物技术开发中心 | 双特异性t细胞活化剂抗体 |
GB2518221A (en) * | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
PL3192812T3 (pl) | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
CN106084062B (zh) * | 2015-04-28 | 2021-04-02 | 荣昌生物制药(烟台)有限公司 | 桥连的双特异性融合蛋白 |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
EP3402519A4 (fr) * | 2016-01-13 | 2020-01-08 | Compass Therapeutics LLC | Constructions de liaison à l'antigène immunomodulateur multispécifique |
JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス,インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
JP2020503260A (ja) | 2016-11-15 | 2020-01-30 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体による処置のための投与 |
US20190330376A1 (en) * | 2016-12-29 | 2019-10-31 | Development Center For Biotechnology | Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions |
CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
EP3619235A1 (fr) * | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Constructions polypeptidiques multispécifiques comprenant une liaison cd3 contrainte et leurs méthodes d'utilisation |
EP3630836A1 (fr) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック, インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
WO2019178364A2 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
WO2019178362A1 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à calréticuline et utilisations associees |
EP3818083A2 (fr) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
US20200048350A1 (en) * | 2018-07-24 | 2020-02-13 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
US20210340273A1 (en) * | 2018-10-11 | 2021-11-04 | Inhlbrx, inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
GB2597851A (en) | 2019-02-21 | 2022-02-09 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
WO2020172596A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
WO2020172571A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
GB2599229B (en) | 2019-02-21 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
GB2599227B (en) | 2019-02-21 | 2024-05-01 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
WO2021138407A2 (fr) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à cd33 et utilisations associées |
EP4139363A1 (fr) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
CN116761818A (zh) | 2020-08-26 | 2023-09-15 | 马伦戈治疗公司 | 检测trbc1或trbc2的方法 |
GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
WO2022046920A2 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656064B1 (fr) * | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Immunoadhesines bispecifiques |
WO1995009917A1 (fr) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Anticorps bispecifiques et tetravalents, obtenus par genie genetique |
EP1294904A1 (fr) * | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Proteines de fusion heterodimeres |
JP5010281B2 (ja) * | 2003-05-31 | 2012-08-29 | マイクロメット アクツィエン ゲゼルシャフト | Epcamに対する二重特異性抗体を含む薬学的組成物 |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007044887A2 (fr) * | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Procede de production d'une population homogene d'anticorps bispecifiques tetravalents |
US20090155275A1 (en) * | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
WO2009082624A2 (fr) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci |
EP2464664B1 (fr) * | 2009-08-13 | 2015-09-23 | Crucell Holland B.V. | Anticorps contre le virus respiratoire syncytial (vrs) humain et procédés d'utilisation |
AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
CN104144949B (zh) * | 2011-12-22 | 2016-08-31 | 财团法人生物技术开发中心 | 双特异性t细胞活化剂抗体 |
-
2012
- 2012-12-27 KR KR1020167034503A patent/KR101814370B1/ko active IP Right Grant
- 2012-12-27 JP JP2014550457A patent/JP6114902B2/ja active Active
- 2012-12-27 KR KR1020147019804A patent/KR20140112515A/ko active Application Filing
- 2012-12-27 TW TW101150846A patent/TWI530505B/zh active
- 2012-12-27 WO PCT/US2012/071780 patent/WO2013101909A1/fr active Application Filing
- 2012-12-27 US US13/728,839 patent/US20130165638A1/en not_active Abandoned
- 2012-12-27 AU AU2012362378A patent/AU2012362378B2/en active Active
- 2012-12-27 CN CN201280064787.7A patent/CN104185642A/zh active Pending
- 2012-12-27 EP EP12863859.0A patent/EP2797958B1/fr active Active
- 2012-12-27 CA CA2861816A patent/CA2861816C/fr active Active
-
2015
- 2015-03-24 HK HK15102984.7A patent/HK1202560A1/xx unknown
-
2016
- 2016-10-07 JP JP2016198979A patent/JP2017048196A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
TW201336866A (zh) | 2013-09-16 |
KR20160145847A (ko) | 2016-12-20 |
EP2797958A4 (fr) | 2015-08-05 |
CA2861816A1 (fr) | 2013-07-04 |
EP2797958A1 (fr) | 2014-11-05 |
AU2012362378A1 (en) | 2014-07-31 |
US20130165638A1 (en) | 2013-06-27 |
KR101814370B1 (ko) | 2018-01-12 |
TWI530505B (zh) | 2016-04-21 |
JP6114902B2 (ja) | 2017-04-19 |
WO2013101909A1 (fr) | 2013-07-04 |
EP2797958B1 (fr) | 2023-07-19 |
CN104185642A (zh) | 2014-12-03 |
JP2017048196A (ja) | 2017-03-09 |
AU2012362378B2 (en) | 2016-06-23 |
JP2015508400A (ja) | 2015-03-19 |
CA2861816C (fr) | 2022-11-08 |
KR20140112515A (ko) | 2014-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202560A1 (en) | Light chain-bridged bispecific antibody | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
EP2922874A4 (fr) | Anticorps bispécifiques | |
ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
SI2794658T1 (sl) | Bispecifična molekula protitelesa | |
HK1182625A1 (en) | Bispecific antibodies | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
EP2711605A4 (fr) | Lampe | |
ZA201407272B (en) | Anti-baff-anti-il-17 bispecific antibodies | |
TWI563004B (en) | Anti-hxcr1 antibody | |
EP2690111A4 (fr) | Anticorps monoclonal de souris anti-aggrus | |
AU339253S (en) | Light | |
EP2769988A4 (fr) | Anticorps anti-gap43 | |
EP2714074A4 (fr) | Anticorps anti-emr1 | |
AU336489S (en) | Light | |
AU336487S (en) | Light | |
AU336488S (en) | Light |